Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Gemini Can Now Generate 30-Second Songs From Text, Images with Lyria 3 You don't have to provide the lyrics. Just mention the mood and tempo or upload an image for reference, and let Lyria 3 do the ...

David Nield is a technology journalist from Manchester in the U.K. who has been writing about gadgets and apps for more than 20 years. He has a bachelor's degree in English Literature from Durham ...

Dina Zipin has 10+ years of experience as a writer and editor and 2+ years as the head writer/creative strategist for Uproxx Media. Suzanne is a content marketer, writer, and fact-checker. She holds a ...

Investing.com - Generate Biomedicines, Inc. filed to raise up to $425 million in an initial public offering on The Nasdaq Stock Market under the symbol "GENB." The clinical-stage generative biology ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...